Investment Rating - The investment rating for the company is "Buy" (首次) [1] Core Insights - The company is a leading small molecule CDMO with over 25 years of experience, currently transitioning from a single small molecule business to a dual-driven model of "small molecule + emerging business" [5][17] - The new business segment is experiencing rapid growth, contributing significantly to revenue, while traditional business remains resilient [5][6] - The company is expected to achieve net profits of 1.16 billion, 1.30 billion, and 1.51 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 3.23, 3.59, and 4.18 yuan [5] Financial Summary and Valuation Metrics - Revenue projections for 2025, 2026, and 2027 are 6.66 billion, 7.69 billion, and 8.94 billion yuan respectively, with year-over-year growth rates of 14.7%, 15.4%, and 16.3% [8] - The company’s gross margin is projected to be around 42% for 2025, with a net margin of 17.5% [8] - The current P/E ratios are 31.0, 27.8, and 23.9 for 2025, 2026, and 2027 respectively [8] Business Development and Strategy - The company is focusing on expanding its capabilities in the peptide and small nucleic acid sectors, with significant investments in production capacity [6][79] - As of H1 2025, the new business segment generated 756 million yuan in revenue, a 51.22% increase year-over-year, accounting for 23.71% of total revenue [6] - The company has established partnerships with major pharmaceutical companies, enhancing its market presence and customer base [44] Industry Trends - The global healthcare investment environment is gradually recovering, with a total investment of 63.88 billion USD in 2025, marking a 10.13% increase year-over-year [47] - The domestic healthcare investment market is also improving, with a total of 73.78 billion yuan in 2025, a 39.05% increase year-over-year [53] - The global CDMO market is expected to grow significantly, with the small molecule CDMO/CMO market projected to reach 112 billion USD by 2029, growing at a CAGR of 16.6% [65]

Summary of Sichuan Shuangma Conference Call Company Overview - Sichuan Shuangma has transformed from a single cement enterprise to a dual-main business company focusing on equity investment and biomedicine, continuously divesting cement assets and actively entering the biomedicine sector through acquisitions like Shenzhen Jianyuan and participation in the acquisition of Wuxi Shengji [2][5]. Core Business Structure - The company's main business structure is divided into three parts: private equity investment (approximately 30% of revenue), biomedicine (approximately 28%), and cement/building materials (approximately 42%) by 2025. The profit contribution from private equity investment is expected to reach around 90%, while the remaining profit will mainly come from biomedicine, with the cement business being flat or slightly loss-making [3]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are expected to be CNY 1.455 billion, CNY 1.802 billion, and CNY 2.587 billion, representing year-on-year growth of 35.37%, 23.85%, and 43.58% respectively. Net profit attributable to the parent company is projected to be CNY 491 million, CNY 1.132 billion, and CNY 1.475 billion, with growth rates of 58.32%, 131.03%, and 30.32% respectively [2][9]. Investment and Growth Strategy - The company has a strong focus on biomedicine as its second main business, with significant acquisitions aimed at accelerating its presence in the sector. The acquisition of Shenzhen Jianyuan for CNY 1.6 billion and participation in the acquisition of Wuxi Shengji are key steps in this strategy [5][8]. Market Perception and Valuation - The market perceives uncertainty regarding the company's equity investment business, particularly due to the low current contribution of the biomedicine sector to overall revenue and profit. Concerns include potential declines in management fee income as the first batch of funds enters the exit phase and the uncertain scale and timing of excess return realizations [2][6]. Value Reassessment Opportunities - There is a belief that Sichuan Shuangma has opportunities for value reassessment due to the high certainty of cash returns from its equity investment business. IDG Capital's strong investment management capabilities and the successful IPOs of several hard-tech projects are expected to provide substantial cash returns, estimated at CNY 10.4 billion from two managed funds [7][9]. Historical Context and Strategic Shift - The entry of IDG in 2016 marked a significant shift for Sichuan Shuangma, transitioning from a cement-focused company to one that also manages equity funds. The company has been divesting outdated cement assets since 2017, with only one cement plant remaining as of 2024 [4]. Conclusion - Sichuan Shuangma's strategic focus on biomedicine and equity investment, combined with strong projected financial growth and potential for value reassessment, positions the company favorably for future performance despite current market uncertainties [2][7].